IDEXX Laboratories, Inc.
IDXX
$567.44
-1.50%
IDEXX Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock, including in-office test kits, benchtop analyzers, reference lab services, and veterinary practice management software. As the global leader in veterinary diagnostics, the company holds a dominant market position with a comprehensive product portfolio and a strong brand among animal hospitals. The current investor narrative centers on resilient demand driven by increased clinical visits and diagnostic frequency, as evidenced by the company's raised guidance following strong Q1 2026 results. Debates persist around margin sustainability and valuation, given the stock's premium multiples and recent price volatility.…
IDXX
IDEXX Laboratories, Inc.
$567.44
Related headlines
IDXX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $708.43 and implied upside of +24.9% versus the current price.
Average Target
$708.43
0 analysts
Implied Upside
+24.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
IDEXX is covered by 14 analysts, with a consensus recommendation of 'Buy' (mean score 2.13 on a 1-5 scale, where 1 is Strong Buy). The average target price is $708.43, implying approximately +24.8% upside from the current price of $567.44. The distribution shows 5 Buy/Overweight ratings and 4 Neutral ratings, with no Sell ratings, indicating a broadly bullish sentiment. The target range spans from a low of $470 to a high of $805. The high target of $805 assumes continued growth acceleration and multiple expansion, while the low target of $470 reflects risks of margin compression or slower demand. The wide spread ($335) signals high uncertainty about the company's future trajectory. Recent ratings actions have been stable, with firms like UBS maintaining Neutral and Barclays and Morgan Stanley reiterating Overweight, suggesting no major shifts in sentiment. The strong buy consensus and significant upside potential make the stock attractive, but the wide range underscores the need for careful risk assessment.
Drowning in data?
Find the real signal!
Bulls vs Bears: IDXX Investment Factors
IDEXX presents a compelling growth story with accelerating revenue, expanding margins, and strong free cash flow, underpinned by its dominant position in veterinary diagnostics. The bull case is supported by raised guidance and analyst consensus Buy with ~25% upside to the average target. However, the stock trades at a significant premium (trailing P/E 51.4x, PEG 2.3x) relative to the sector, and recent price underperformance and high beta introduce substantial risk. The central tension is whether the company's growth trajectory can justify its elevated valuation—if growth continues to accelerate, the stock could re-rate higher; if growth slows, multiple compression could lead to significant downside. Currently, the evidence slightly favors the bull case given the fundamental momentum, but the valuation premium keeps the risk elevated.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 14.26% YoY to $1.14B, accelerating from 9.5% in Q4 2025 and 13.4% in Q3 2025, driven by higher clinical visits and diagnostic frequency. This trend supports the bullish thesis of resilient pet healthcare demand.
- Expanding Profit Margins: Gross margin improved to 63.4% in Q1 2026 from 60.3% in Q4 2025, and operating margin rose to 31.8% from 28.9%. Net margin reached 24.4%, up from 22.8%, indicating strong pricing power and operational leverage.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow is $1.08B, with Q1 2026 FCF of $234M. This provides ample capacity for internal growth, share repurchases, and debt reduction, enhancing shareholder value.
- Dominant Market Position: IDEXX is the global leader in veterinary diagnostics with a comprehensive product portfolio and strong brand among animal hospitals. This competitive moat supports sustained pricing power and customer loyalty.
Bearish
- Premium Valuation Multiples: Trailing P/E of 51.4x and forward P/E of 34.4x are well above the medical diagnostics sector average of ~20-25x. P/S of 12.6x is ~3x the sector median, leaving little room for error.
- PEG Ratio Above 2 Suggests Overpricing: PEG ratio of 2.3x indicates the stock is priced above its growth rate, implying that even after adjusting for expected EPS growth, the stock is not cheap. This limits upside if growth decelerates.
- Recent Price Underperformance: IDXX has underperformed the S&P 500 by -8.96% over the past year and -8.37% over 3 months. The stock is 26.3% below its 52-week high of $769.98, reflecting persistent selling pressure.
- High Beta Amplifies Downside Risk: With a beta of 1.549, IDXX is 55% more volatile than the market. In a broad market downturn, the stock could decline significantly more than the index, as seen in its 31.34% max drawdown.
IDXX Technical Analysis
IDEXX is in a sustained uptrend over the past year, with a 1-year price change of +9.39%. The current price of $567.44 sits at approximately 15.5% above the 52-week low of $513.02 and 26.3% below the 52-week high of $769.98, placing it in the lower half of its range. This positioning suggests the stock is in a corrective phase within a longer-term uptrend, potentially offering a value entry if the trend resumes, but also reflecting lingering bearish sentiment after a significant peak. Short-term momentum is mixed: the 1-month change is +3.91%, indicating a recent bounce, while the 3-month change is -3.70%, showing continued weakness. This divergence—positive short-term but negative medium-term—could signal a temporary pullback within a larger downtrend or the early stages of a reversal. The stock's relative strength versus the S&P 500 is negative over 3 months (-8.37%) and 1 year (-8.96%), confirming underperformance. The 52-week low of $513.02 provides key support, while the 52-week high of $769.98 is the primary resistance. A breakout above $770 would signal a resumption of the long-term uptrend, while a breakdown below $513 could indicate further downside. With a beta of 1.549, IDEXX is 55% more volatile than the market, amplifying both upside and downside moves, which is critical for risk management.
Beta
1.55
1.55x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$513-$770
Price range past year
Annual Return
+9.4%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | -0.5% |
| 3m | -3.7% | +4.9% |
| 6m | -20.7% | +9.7% |
| 1y | +9.4% | +18.4% |
| ytd | -15.3% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
Revenue growth is solid and accelerating: Q1 2026 revenue of $1.14 billion grew 14.26% year-over-year, up from 9.5% growth in Q4 2025 and 13.4% in Q3 2025. The trailing twelve-month revenue reached approximately $4.45 billion, driven by both product sales ($666 million in Q1) and service revenue ($475 million). This acceleration reflects higher clinical visit volumes and increased diagnostic frequency, supporting the bullish narrative. Profitability is robust: Q1 2026 net income was $278.4 million, with a net margin of 24.4%, up from 22.8% in Q4 2025. Gross margin improved to 63.4% from 60.3% in Q4 2025, while operating margin expanded to 31.8% from 28.9%. The company has consistently delivered net margins above 20% over the past four quarters, indicating strong pricing power and operational efficiency. The balance sheet is healthy: debt-to-equity is 0.67, and the current ratio is 1.17, indicating adequate liquidity. Free cash flow for Q1 2026 was $234 million, and trailing twelve-month FCF reached $1.08 billion, providing ample capacity for internal growth and share repurchases. ROE is exceptionally high at 66.0%, reflecting efficient capital use, though leverage from share buybacks contributes to this figure.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 51.4x, while the forward P/E is 34.4x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests analysts anticipate a 33% EPS increase over the next year, which is aggressive but supported by recent guidance. Compared to the industry, IDEXX trades at a substantial premium: the P/S ratio of 12.6x is far above the medical diagnostics sector average of roughly 4-5x, reflecting its market leadership and high margins. The PEG ratio of 2.3x indicates the stock is priced above its growth rate, suggesting it is not cheap even on a growth-adjusted basis. Historically, the current trailing P/E of 51.4x is below its 5-year average of around 55x and well below the peak of 86x in late 2021. This suggests valuation has compressed from historical highs, potentially offering a more reasonable entry point, though still elevated in absolute terms. The P/B ratio of 33.8x is also near the lower end of its historical range (21x to 80x), indicating less premium on book value.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IDEXX carries a debt-to-equity ratio of 0.67, which is manageable but not negligible. The company's high ROE of 66% is partly driven by share buybacks and leverage, which could amplify earnings volatility. While free cash flow is strong at $1.08B TTM, any slowdown in revenue growth could pressure margins and cash generation. The net margin of 24.4% is high but could compress if competition intensifies or input costs rise. Revenue concentration in the pet diagnostic market (35% international) exposes the company to currency fluctuations and regional economic downturns.
Market & Competitive Risks: The stock's premium valuation (trailing P/E 51.4x vs. sector ~20x) makes it vulnerable to multiple compression if growth disappoints. With a beta of 1.549, IDXX is highly correlated with market movements, and a broad sell-off could amplify losses. Competitive threats from new entrants or alternative diagnostic technologies could erode market share. Regulatory risks include changes in veterinary practice standards or pet health insurance policies that could affect visit frequency. Recent news of raised guidance is positive, but any negative surprise in future quarters could trigger sharp sell-offs.
Worst-Case Scenario: A combination of slowing clinical visit growth, margin compression from competition, and a broad market downturn could drive the stock to its 52-week low of $513.02, representing a -9.6% decline from the current price of $567.44. In a more severe scenario, if the company misses earnings and guidance, the stock could fall to the analyst low target of $470, a -17.2% loss. Historical max drawdown of -31.34% suggests that in a prolonged bear market, losses could exceed 30%, potentially bringing the stock below $400.
